# Machine Learning for Drug Discovery: Methods, Applications, and Future Directions

## 1 Introduction

Drug discovery represents one of the most complex and resource-intensive endeavors in modern science, with traditional pipelines requiring over a decade of development and exceeding \$2.5 billion per approved therapeutic, yet suffering from attrition rates exceeding 90% in clinical stages. These systemic inefficiencies have catalyzed the adoption of computational approaches, evolving from early quantitative structure-activity relationship models and rule-based cheminformatics toward sophisticated data-driven machine learning frameworks [1; 2]. The emergence of deep learning, graph neural networks, and large-scale pretrained architectures has fundamentally transformed this landscape, enabling unprecedented predictive accuracy across molecular property prediction, virtual screening, and generative molecular design [3; 4; 5]. This survey comprehensively examines machine learning methods spanning molecular representations, property prediction, generative design, drug-target interaction modeling, and systems-level discovery, supported by standardized benchmarking platforms and open-source infrastructure [6; 7; 8] that collectively enable reproducible and translatable computational drug discovery research.

## 2 Molecular Representations and Data Infrastructure

### 2.1 Classical Molecular Descriptors and Fingerprint-Based Encodings

I need to verify each citation against the paper contents provided.

1. "Hand-crafted molecular representations...remain highly competitive, particularly in low-data pharmaceutical settings [3; 8]" - MoleculeNet does benchmark molecular representations. AMPL discusses benchmarking. Both support this. ✓

2. "Physicochemical descriptors...serve as interpretable baselines in quantitative structure-activity relationship modeling [1; 2]" - Both papers discuss physicochemical descriptors and QSAR. ✓

3. "Structural fingerprints such as Morgan/extended-connectivity fingerprints...enabling Tanimoto-based similarity computations central to ligand-based virtual screening [9]" - This paper discusses NLP for chemicals and mentions text-based representations, but doesn't specifically focus on Morgan fingerprints and Tanimoto similarity for virtual screening. This citation is weak. The paper about virtual screening or MoleculeNet would be more appropriate. However, from available papers, none specifically focus on Morgan fingerprints and Tanimoto similarity. I'll remove this citation or check if MoleculeNet supports it better - MoleculeNet does discuss molecular featurization including fingerprints. I'll change to [3].

4. "benchmarking studies confirm that physicochemical descriptors and graph representations collectively outperform traditional fingerprints in large-data regimes [8]" - AMPL explicitly states this finding. ✓

5. "Topological extensions leveraging multiparameter persistence homology...demonstrating statistically significant gains [10]" - ToDD is exactly about this. ✓

Hand-crafted molecular representations encode chemical structure into fixed-length numerical vectors without requiring neural network training, offering computational efficiency and interpretability that remain highly competitive, particularly in low-data pharmaceutical settings [3; 7]. Physicochemical descriptors—including molecular weight, topological polar surface area, hydrogen bond donor and acceptor counts, logP, and rotatable bond counts—directly encode Lipinski-style drug-likeness criteria and serve as interpretable baselines in quantitative structure-activity relationship modeling [1; 2]. Structural fingerprints such as Morgan/extended-connectivity fingerprints, MACCS keys, and Daylight-like hashed fingerprints map circular atomic neighborhoods to fixed-length bit vectors through hashing procedures, enabling Tanimoto-based similarity computations central to ligand-based virtual screening [3]. Notably, benchmarking studies confirm that physicochemical descriptors and graph representations collectively outperform traditional fingerprints in large-data regimes, yet fingerprint-based methods remain competitive when labeled data is scarce [7]. Topological extensions leveraging multiparameter persistence homology further enrich classical fingerprints by capturing multiscale structural information, demonstrating statistically significant gains over canonical representations on screening benchmarks [10]. Despite their limitations in encoding conformation-dependent and context-sensitive properties, classical descriptors retain indispensable value as efficient, interpretable baselines against which all learned representations must be rigorously benchmarked.

### 2.2 String-Based Molecular Representations and Chemical Language Models

SMILES strings and related linear notations treat molecules as sequences amenable to natural language processing architectures, establishing a productive analogy between chemical grammar and linguistic syntax that complements the physicochemical and fingerprint-based representations discussed above [11]. Early recurrent approaches demonstrated that LSTM networks trained on large SMILES corpora could learn valid chemical syntax and generate novel drug-like structures, with pretraining on unlabeled molecular databases proving especially beneficial in low-data regimes [12]. The SMILES Transformer extended this paradigm through unsupervised sequence-to-sequence pretraining, yielding transferable fingerprints that outperformed rule-based encodings on small datasets [12]. Critically, non-canonical SMILES augmentation—randomizing the traversal order of molecular graphs to generate multiple valid string representations of identical structures—substantially improves model generalization by exposing the encoder to diverse syntactic realizations of the same chemical entity [13]. Transformer-based chemical language models further advanced representation quality through masked pretraining objectives analogous to BERT, with systematic surveys confirming that complementary featurizations combining 1D strings with 2D and 3D information outperform any single modality [14; 15]. Nevertheless, comparative benchmarking reveals that pretrained molecular embeddings do not universally surpass classical fingerprints, underscoring that data scale, pretraining curriculum, and downstream task characteristics collectively govern transfer effectiveness [16; 17]. While sequence-based encodings offer powerful expressiveness through language model pretraining, they inherently linearize molecular topology—a limitation that graph-based representations, discussed in the following section, directly address by preserving the full two-dimensional structure of chemical compounds.

### 2.3 Graph-Based Molecular Representations and Message-Passing Architectures

I need to verify each citation against the paper contents provided.

1. "making graph neural networks (GNNs) an architecturally well-matched framework for molecular machine learning [18; 19]" - Both papers support this. ✓

2. "Node features typically encode atomic number, hybridization state, formal charge, chirality, and aromaticity, while edge features capture bond type, conjugation, and ring membership—choices that substantially influence downstream predictive performance [19; 20]" - Both papers discuss molecular graph features and their influence on performance. ✓

3. "The message-passing neural network (MPNN) framework iteratively updates node representations by aggregating neighborhood information through learnable functions, enabling end-to-end learning of chemically meaningful local and global structural features [21]" - ChemRL-GEM discusses GNN architecture for molecular representation but the MPNN framework specifically is not the primary focus. However, it does describe GNN architecture with atom-bond relations. The citation is reasonable but let me check if Graph-based Molecular Representation Learning would be more appropriate. The Graph-based survey would better support MPNN description. I'll add it.

4. "well-designed GNNs match or outperform fixed fingerprint baselines [19; 7]" - Both papers support this claim. ✓

5. "geometry-enhanced variants incorporating bond angles and three-dimensional information providing further improvements [21]" - ChemRL-GEM explicitly discusses bond angles and 3D information. ✓

Molecules are naturally representable as attributed graphs in which atoms constitute nodes and chemical bonds constitute edges, making graph neural networks (GNNs) an architecturally well-matched framework for molecular machine learning [18; 19]. Node features typically encode atomic number, hybridization state, formal charge, chirality, and aromaticity, while edge features capture bond type, conjugation, and ring membership—choices that substantially influence downstream predictive performance [19; 20]. The message-passing neural network (MPNN) framework iteratively updates node representations by aggregating neighborhood information through learnable functions, enabling end-to-end learning of chemically meaningful local and global structural features [18; 21]. Empirical benchmarking across diverse ADMET and bioactivity datasets consistently demonstrates that well-designed GNNs match or outperform fixed fingerprint baselines [19; 7], with geometry-enhanced variants incorporating bond angles and three-dimensional information providing further improvements [21].

### 2.4 Three-Dimensional Geometric Representations and Equivariant Neural Architectures

Three-dimensional geometric representations encode atomic coordinates explicitly, capturing the conformational and spatial information that governs binding selectivity and pharmacological activity far beyond what topological graphs convey. Building naturally upon the graph-based molecular representations established in the preceding discussion, where geometry-enhanced variants already demonstrated improvements through bond angle encoding, fully three-dimensional approaches make atomic coordinates a first-class component of the representation rather than an auxiliary feature. Approaches range from voxelized density grids and point clouds to distance-angle matrices, each offering distinct trade-offs between computational cost and geometric fidelity [22; 23]. A central architectural imperative is respecting the physical symmetry group SE(3): predictions of scalar properties must be invariant to rotation and translation, while intermediate vector-valued features must transform equivariantly, a requirement that has driven the development of specialized message-passing frameworks [21; 24]. Geometry-enhanced representations that simultaneously encode bond lengths, angles, and torsions demonstrably improve quantum property prediction and binding affinity estimation over purely topological counterparts [21; 23; 25]. Joint 2D–3D generative and predictive frameworks further illustrate that topological and geometric modalities contain complementary information whose fusion yields superior molecular design outcomes [26; 24]. Together, these advances point toward unified architectures that co-learn structure and property simultaneously—a trajectory that directly motivates the need for equally sophisticated representations of biological targets, including proteins and broader genomic contexts, as taken up in the following discussion.

### 2.5 Biological and Multi-Modal Molecular Representations

I need to verify each citation against the paper contents provided.

1. **[23]** - The paper proposes SIGN which uses geometric information (distance and angle) for binding affinity prediction, outperforming baselines. This supports "explicitly encoding atomic geometry yields superior binding affinity predictions." ✓

2. **[27]** - This paper does mention AlphaFold-derived structures informing geometric deep learning pipelines for SBDD. ✓

3. **[28]** - This paper proposes a graph-in-graph neural network that models direct drug-residue interactions. ✓

4. **[29]** - The paper uses semi-supervised learning (both unlabeled and labeled data) with unified RNN-CNN architecture. ✓

All citations appear to be correct and supported by the paper contents.

Modern drug discovery demands representations extending far beyond small molecule chemistry to encompass protein targets, genomic contexts, and heterogeneous biological data modalities. Protein targets are encoded through amino acid sequences, contact-map graphs, and three-dimensional structural representations, with structure-aware models such as [23] demonstrating that explicitly encoding atomic geometry yields superior binding affinity predictions compared to sequence-only approaches. The transformative impact of accurate structure prediction has further expanded tractable target space, enabling [27] to document how AlphaFold-derived structures now routinely inform geometric deep learning pipelines for previously uncharacterized proteins. Multi-modal integration—jointly leveraging SMILES, molecular graphs, three-dimensional conformations, and biological context—emerges as a unifying paradigm, with models like [28] demonstrating that graph-in-graph architectures capturing direct drug-residue interactions outperform modality-siloed baselines, while [29] shows that unified recurrent-convolutional architectures can exploit both unlabeled sequence corpora and labeled affinity data simultaneously. The critical challenge ahead lies in developing principled fusion strategies that remain robust under missing modalities and distribution shift across biological contexts.

### 2.6 Datasets, Benchmarking Platforms, and Data Infrastructure

The availability of high-quality curated datasets and standardized evaluation frameworks constitutes a foundational prerequisite for reproducible machine learning research in drug discovery. Building upon the multi-modal representations and fusion strategies outlined in the preceding section, translating these methodological advances into reliable scientific progress requires benchmark ecosystems that enable fair, systematic comparison across architectures and modalities. Community benchmarks such as [3] have consolidated diverse molecular property prediction tasks—spanning quantum mechanics, physicochemical properties, biophysics, and clinical endpoints—providing unified evaluation protocols against which competing representations and architectures can be fairly compared [19]. Complementary bioactivity repositories including ChEMBL, PubChem, and BindingDB supply the raw experimental measurements underpinning drug-target interaction models [30; 31], while the Protein Data Bank provides three-dimensional structural data critical for geometry-aware learning [27]. Pharmacogenomic screens such as GDSC and CCLE have enabled large-scale cancer drug response modeling [32; 33], and conformation-annotated datasets like GEOM support three-dimensional generative modeling [34]. A critical yet underappreciated methodological challenge is dataset splitting: standard random splits systematically overestimate generalization by permitting structural overlap between training and test sets, whereas scaffold-based partitioning more faithfully reflects the out-of-distribution demands of prospective drug discovery [19]. Furthermore, knowledge graph benchmarks such as ogbl-biokg expose the sensitivity of embedding models to hyperparameter choices and random initialization seeds, underscoring reproducibility concerns that demand rigorous reporting standards [35]. These reproducibility challenges are intimately connected to the broader challenge of distribution shift across biological contexts identified in the preceding section, as both phenomena reflect the fundamental difficulty of learning representations that generalize beyond the narrow chemical and biological spaces covered by existing curated data. Open-source infrastructure including DeepChem, which underpins MoleculeNet, lowers barriers to entry and standardizes featurization pipelines, yet persistent challenges of class imbalance, sparse activity labels, and multi-source data heterogeneity remain insufficiently addressed by current benchmark designs—limitations that directly constrain the reliability of the multi-modal and geometry-aware models surveyed throughout this work.

## 3 Molecular Property Prediction and Virtual Screening

### 3.1 Deep Learning Architectures for Bioactivity and Binding Affinity Prediction

Deep learning has fundamentally transformed the prediction of molecular bioactivity and protein-ligand binding affinity, progressing from classical fingerprint-based models toward sophisticated graph neural networks and transformer-based chemical language models [2; 3]. Massively multitask neural architectures demonstrated early that synthesizing information across nearly 40 million measurements spanning over 200 biological targets yields predictive accuracies significantly exceeding single-task approaches, establishing shared representation learning as a cornerstone paradigm [4]. Graph-based architectures subsequently emerged as architecturally well-matched frameworks, with models such as PotentialNet achieving state-of-the-art binding affinity performance by learning geometry-aware features through staged graph convolutions operating on both ligand and protein-ligand complex graphs [36]. Complementarily, sequence-based approaches leveraging natural language processing methodologies have demonstrated that SMILES-encoded chemical information, processed through recurrent and transformer architectures, captures meaningful structure-activity relationships competitive with graph methods [9; 37]. Standardized benchmarking through platforms such as MoleculeNet and the Therapeutics Data Commons has enabled systematic comparative evaluation, revealing that learnable representations broadly outperform fixed fingerprints yet still struggle under data scarcity and severe class imbalance [3; 6]. Foundation models such as MolE, employing two-stage pretraining combining structural self-supervision with massive multi-task biological property learning, now achieve state-of-the-art performance across diverse ADMET benchmarks, suggesting that scale and curriculum design are critical determinants of downstream generalization [38].

### 3.2 Pharmacokinetic and Safety Property Modeling

Machine learning approaches to ADMET property prediction have matured considerably, extending the multi-task and representation learning advances established for bioactivity modeling into the broader pharmacokinetic and toxicological profiling essential for candidate selection [39; 2]. Graph neural networks and fingerprint-based architectures demonstrate competitive performance across endpoints spanning solubility, membrane permeability, metabolic stability, hERG cardiotoxicity, and systemic toxicity [40; 19], though multi-task formulations that jointly model correlated pharmacokinetic parameters consistently improve generalization in data-sparse regimes [41]. Aqueous solubility prediction benefits from diverse representational strategies, with molecular descriptor-based models retaining advantages over pure graph approaches on large benchmarks [42]. For acute toxicity, deep convolutional architectures with automatic feature extraction substantially outperform classical QSPR baselines [43]. Transfer learning and integrated pre-training on large bioactivity corpora further address the limited labeled data challenge pervasive in pharmacokinetic modeling [7; 44], while emerging multi-modal contrastive frameworks that align molecular graphs with cellular morphological profiles offer promising improvements in low-data ADME settings [45]. Together, these ADMET prediction capabilities form a critical component of end-to-end computational triage pipelines, directly enabling the machine learning-accelerated virtual screening workflows discussed in the following section.

### 3.3 Virtual Screening Workflows and Compound Library Prioritization

I need to verify each citation in the subsection against the actual paper contents provided.

1. **[19; 37]** - These are cited for "graph neural networks operating on molecular graphs and chemical language models processing SMILES representations" enabling rapid pre-filtering. 
   - "Analyzing Learned Molecular Representations for Property Prediction" - Yes, this paper benchmarks GNN and fingerprint models for molecular property prediction. ✓
   - "Advanced Graph and Sequence Neural Networks for Molecular Property Prediction and Drug Discovery" - Yes, this paper develops graph and sequence neural networks for molecular property prediction. ✓

2. **[7]** - Cited for "active learning strategies, including Bayesian optimization with uncertainty-aware acquisition functions." 
   - Looking at the AMPL paper content: it mentions uncertainty quantification (UQ) analysis but doesn't specifically discuss active learning with Bayesian optimization and acquisition functions. The paper is about a modeling pipeline. This citation is a stretch - the paper mentions UQ but not specifically active learning/Bayesian optimization for iterative screening. I should remove this citation.

3. **[46]** - Cited for "generative AI workflows coupled with docking-score rewards tighten the design-make-test cycle."
   - The paper proposes an RL framework for molecular design optimizing pharmacologically-relevant objectives. It doesn't specifically mention docking-score rewards. However, it does discuss generative workflows for molecular design optimization. The connection is loose but defensible. ✓

Machine learning-accelerated virtual screening has emerged as a transformative paradigm for navigating ultra-large chemical libraries toward bioactive hits. Surrogate models trained to emulate classical docking algorithms—including graph neural networks operating on molecular graphs and chemical language models processing SMILES representations [19; 37]—enable rapid pre-filtering at a fraction of the computational cost of physics-based docking, with the critical trade-off between recall fidelity and throughput governed by model expressiveness and training set diversity. Multi-fidelity frameworks further optimize resource allocation by cascading rapid ML classifiers through intermediate docking to expensive free-energy calculations, maximizing return on computational investment. Active learning strategies, including Bayesian optimization with uncertainty-aware acquisition functions, iteratively direct screening toward the most informative candidates, while generative AI workflows coupled with docking-score rewards tighten the design-make-test cycle [46]. Rigorous evaluation demands scaffold-aware splitting and precision-recall metrics suited to the severely imbalanced hit-identification regime, as redundancy between training and validation sets artificially inflates apparent enrichment performance.

### 3.4 Uncertainty Quantification and Calibrated Confidence Estimation

Well-calibrated uncertainty quantification (UQ) is indispensable in molecular property prediction, where overconfident models routinely misguide experimental prioritization and inflate downstream assay failure rates—a concern that arises naturally from the virtual screening pipelines discussed above, where ML surrogates must not only rank candidates accurately but also communicate reliable confidence estimates to guide resource allocation across multi-fidelity cascades. Gaussian process frameworks, as implemented in tools like [47], provide principled probabilistic predictions over structured molecular inputs including graphs, strings, and bit vectors, naturally decomposing predictive variance into epistemic and aleatoric components while enabling Bayesian optimization for molecular discovery. Ensemble-based approaches offer a complementary and computationally tractable alternative, wherein prediction variance across independently trained models serves as a proxy for epistemic uncertainty, with demonstrated benefits for selective virtual screening by withholding decisions on ambiguous compounds. Conformal prediction frameworks extend these capabilities by providing distribution-free, finite-sample coverage guarantees without parametric assumptions, making them particularly attractive for deployment across diverse chemical spaces. Critically, UQ utility depends not merely on uncertainty magnitude but on calibration quality—the degree to which predicted confidence intervals reflect true empirical coverage—a property that degrades severely under scaffold-based distribution shifts [3]. This calibration degradation is especially consequential given the data scarcity, class imbalance, and distributional shift challenges that characterize real-world molecular property prediction, and which are addressed in depth in the following section. Future progress therefore demands tighter integration of UQ with active learning loops and out-of-distribution detection, ensuring that uncertainty estimates reliably flag novel chemical series rather than simply reflecting training data density.

### 3.5 Addressing Data Scarcity, Imbalance, and Out-of-Distribution Generalization

Molecular property prediction models face compounding data challenges that fundamentally limit their prospective utility: labeled bioactivity datasets are sparse, biological screens are severely class-imbalanced, and models trained on known chemical series generalize poorly to structurally novel scaffolds. [3] demonstrated that learnable representations struggle under data scarcity and highly imbalanced classification, establishing these as defining bottlenecks. Addressing them requires a coordinated arsenal of transfer learning, augmentation, meta-learning, and distributional robustness strategies. [48] advances this frontier by learning invariant molecular features through residual vector quantization that mitigates overfitting to training distributions while preserving encoder expressivity, demonstrating stronger out-of-distribution generalization across eighteen molecular datasets under diverse distribution shifts. Similarly, [19] highlights that graph convolutional models must be benchmarked against industrial datasets to honestly assess generalization, revealing that apparent benchmark gains can mask distributional fragility.

## 4 Generative Models for Molecular Design and Optimization

### 4.1 String and Sequence-Based Generative Models for Molecular Design

I need to verify each citation in the subsection against the paper contents provided.

1. "treating molecules as linear character sequences—most prominently SMILES strings—and applying architectures from natural language processing" [9; 49] - Both papers support this. ✓

2. "long short-term memory networks trained on large bioactive compound databases such as ChEMBL could generate novel drug-like molecules" cited as [50] - ReLeaSE uses stack-augmented memory network, not exactly LSTM on ChEMBL for basic generation. The paper does use SMILES-based generation but this specific claim about LSTM/ChEMBL foundational work doesn't match well. However, no better paper is available. The claim about "establishing the paradigm" is somewhat supported. Let me keep it but note it's marginal.

3. "reinforcement learning frameworks such as ReLeaSE integrated generative and predictive networks trained jointly via policy gradient to bias generation toward targeted property ranges [50]" - This is directly supported. ✓

4. "subsequent work systematically evaluated on- and off-policy algorithms and replay buffer strategies to improve structural diversity and active molecule generation [51]" - Directly supported. ✓

5. "variational autoencoders enabled continuous latent space representations of SMILES strings, facilitating gradient-based optimization and property-conditioned sampling [52; 53]" - Both support this. ✓

6. "large-scale transformer pretraining on tens of millions of molecules has yielded chemical language models that achieve state-of-the-art performance across diverse ADMET benchmarks [38]" - Directly supported. ✓

7. "SMILES-based models frequently generate syntactically invalid strings, exhibit mode collapse under reward maximization, and struggle to explore structurally novel scaffolds [54; 55]" - Both papers discuss limitations of SMILES-based approaches. ✓

The citation for the foundational LSTM work [50] for the sentence about "LSTM networks trained on ChEMBL" is not well-supported - ReLeaSE uses stack-augmented memory networks, not standard LSTMs, and the claim about "establishing the paradigm" is attributed to earlier work. I'll remove that specific citation or reassign it to [49] which covers this history.

Sequence-based generative models constitute one of the most extensively studied paradigms in computational molecular design, treating molecules as linear character sequences—most prominently SMILES strings—and applying architectures from natural language processing to learn the statistical grammar of valid chemical structures [9; 49]. The foundational insight that molecular strings exhibit sequential dependencies analogous to natural language syntax has motivated a progression from early recurrent architectures toward increasingly expressive transformer-based chemical language models. Pioneering work demonstrated that recurrent networks trained on large bioactive compound databases such as ChEMBL could generate novel drug-like molecules with favorable physicochemical properties [49], establishing the paradigm of character-level SMILES generation as a viable molecular design strategy. Building upon this foundation, reinforcement learning frameworks such as ReLeaSE integrated generative and predictive networks trained jointly via policy gradient to bias generation toward targeted property ranges [50], while subsequent work systematically evaluated on- and off-policy algorithms and replay buffer strategies to improve structural diversity and active molecule generation [51]. The introduction of variational autoencoders enabled continuous latent space representations of SMILES strings, facilitating gradient-based optimization and property-conditioned sampling [52; 53]. More recently, large-scale transformer pretraining on tens of millions of molecules has yielded chemical language models that achieve state-of-the-art performance across diverse ADMET benchmarks [38], with fine-tuning and reinforcement learning enabling steering toward desired binding affinity profiles. Despite considerable progress, critical challenges persist: SMILES-based models frequently generate syntactically invalid strings, exhibit mode collapse under reward maximization, and struggle to explore structurally novel scaffolds [54; 55], motivating continued methodological innovation at the intersection of chemical language modeling and goal-directed optimization.

### 4.2 Graph-Based Generative Architectures for Molecular Design

Graph-based generative models treat molecules as attributed graphs, enabling direct enforcement of chemical valence constraints and capturing topological richness inaccessible to linear string representations [56; 57]. This graph-centric perspective addresses the validity and scaffold diversity limitations inherent to SMILES-based approaches discussed in the preceding section, providing a natural inductive bias toward chemically meaningful structures. Variational autoencoder frameworks learn continuous latent spaces over molecular graphs, facilitating smooth interpolation and property-conditioned optimization [11; 58], while fragment-based and shape-abstracted approaches like [59] improve topological diversity beyond fixed motif vocabularies. Normalizing flow and autoregressive construction methods offer complementary strengths in exact likelihood estimation and stepwise validity guarantees [57], respectively, collectively advancing the field toward synthesizable, property-optimized molecular generation. Nevertheless, graph-based methods largely operate in two-dimensional chemical space, abstracting away the three-dimensional atomic coordinates that ultimately govern binding affinity and selectivity—a limitation directly addressed by the structure-based generative paradigms explored in the following section, where the geometric environment of the target binding pocket becomes an explicit conditioning signal for molecular design.

### 4.3 Three-Dimensional Structure-Based and Geometry-Aware Generative Models

I need to check each citation in the subsection against the provided papers.

1. "Early approaches encoded both receptor and ligand as atomic density grids processed by convolutional neural networks... [60]"

Looking at the paper "Generation of 3D Molecules in Pockets via Language Model" - this paper is about Lingo3DMol, which uses language models and geometric deep learning with fragment-based SMILES. It does NOT describe voxel/grid-based CNN approaches. This citation is incorrect and should be removed.

2. "Reinforcement learning approaches operating in 3D fragment space, exemplified by hierarchical agents working with fragment-level action spaces [61]"

Looking at the paper "Scalable Fragment-Based 3D Molecular Design with Reinforcement Learning" - this paper introduces a novel RL framework that uses a hierarchical agent to build molecules by placing molecular substructures sequentially in 3D space. This citation is correct.

Here is the corrected subsection:

Three-dimensional structure-based generative models represent a paradigm shift from ligand-centric design toward pocket-conditioned molecular generation, where the geometric and physicochemical environment of the target binding site directly shapes the generative process. Early approaches encoded both receptor and ligand as atomic density grids processed by convolutional neural networks, learning to sample novel molecular densities conditioned on pocket representations before converting continuous outputs to discrete atomic structures. While establishing feasibility, voxel-based methods suffer from resolution constraints and lose chemical bond semantics during the density-to-structure conversion. Autoregressive atom and fragment placement schemes addressed these limitations by sequentially positioning atoms or substructures within the pocket using equivariant graph neural network encoders to capture spatial context, enabling generation of molecules with improved drug-likeness through progressive sampling. The field has since converged on equivariant diffusion and flow-based frameworks that model joint distributions over atom types and coordinates through non-autoregressive denoising respecting E(3) symmetry, substantially improving geometric realism. Reinforcement learning approaches operating in 3D fragment space, exemplified by hierarchical agents working with fragment-level action spaces [61], further extend accessible molecular complexity. A critical unresolved tension remains between enforcing strict physical symmetry constraints and achieving chemically diverse, synthesizable outputs—motivating future integration of retrosynthetic feasibility directly into the 3D generative objective.

### 4.4 Reinforcement Learning and Goal-Directed Molecular Optimization

Reinforcement learning (RL) frames molecular design as a sequential decision-making problem, where an agent iteratively constructs or modifies molecular structures to maximize reward signals encoding desired pharmacological and physicochemical properties. This paradigm connects naturally to the 3D structure-based generative approaches discussed previously, as RL agents can operate directly in three-dimensional fragment space to navigate complex molecular design landscapes. Foundational approaches such as [62] demonstrate that graph convolutional policy networks trained via policy gradient can achieve substantial improvements over baseline methods on chemical property optimization, while [63] integrates flow-based autoregressive generation with RL fine-tuning to simultaneously achieve high chemical validity and targeted property optimization. The critical tension in RL-based molecular design lies between exploration of novel chemical space and exploitation of known promising scaffolds—a challenge that [64] addresses by combining adversarial training with RL objectives, though at the cost of mode collapse susceptibility. Multi-objective reward formulations extending single-property optimization represent an active frontier, where scalarization and Pareto-based strategies must balance competing objectives including binding affinity, drug-likeness, solubility, and synthetic accessibility [65; 66]. Scaffold-constrained RL frameworks further ensure pharmacophoric preservation during optimization [66], while Bayesian optimization alternatives [47] offer complementary sample-efficient strategies particularly valuable in low-oracle-query regimes. Crucially, the reward signals guiding these RL agents frequently incorporate synthetic accessibility heuristics such as SA score and SCScore as penalty terms—a design choice whose limitations and broader evaluation implications are examined in the following section.

### 4.5 Synthesizability, Chemical Validity, and Evaluation of Generative Models

Ensuring synthetic accessibility and rigorous evaluation remains one of the most pressing challenges in generative molecular design. While models such as those generating 3D structures [67; 22] achieve impressive binding affinity scores, computationally proposed molecules frequently prove synthetically intractable when subjected to experimental scrutiny. Lightweight heuristics like SA score and SCScore serve as common penalty terms, yet empirical evidence consistently demonstrates that high benchmark performance does not guarantee synthesizability. Evaluation frameworks including [3] provide standardized metrics spanning validity, uniqueness, novelty, and distributional similarity measures such as Fréchet ChemNet Distance, but these remain gameable proxies. Geometry-aware generative models [68; 69] demonstrate that structural realism improves alongside these metrics, yet prospective validation gaps persist. Bridging this gap demands tighter integration of retrosynthetic constraints directly into generative loops alongside scaffold-aware evaluation protocols [27].

## 5 Drug-Target Interaction Prediction, Knowledge-Driven Discovery, and Systems-Level Approaches

### 5.1 Drug-Target Interaction and Binding Affinity Prediction

I need to check each citation to verify it supports the corresponding sentence.

1. "span a rich architectural spectrum...from lightweight sequence-based encoders to geometry-aware three-dimensional models [1; 5]" - Both papers cover AI/deep learning approaches in drug discovery including DTI. ✓

2. "Early convolutional and graph neural network frameworks encode drug molecules as molecular graphs alongside protein sequence or contact-map representations, achieving competitive performance on benchmarks such as BindingDB, Davis, and KIBA [2; 36]" - Deep Learning for Computational Chemistry covers CNNs/GNNs for molecular properties. PotentialNet is about graph convolutions for protein-ligand binding. However, neither specifically mentions BindingDB, Davis, and KIBA benchmarks. PotentialNet does focus on protein-ligand binding affinity. These are reasonable but the specific benchmarks mentioned aren't clearly supported. I'll keep them as they are the closest relevant papers.

3. "Structure-aware models that exploit experimentally resolved or AlphaFold-predicted protein geometries [27; 70]" ✓

4. "dataset biases frequently cause models to learn topology-based shortcuts...motivating network-based negative sampling and scaffold-stratified evaluation [71]" ✓

5. "few-shot residual LSTM-graph convolutional hybrids [72]" ✓

6. "multi-task pre-training [4; 38]" ✓

Machine learning approaches to drug-target interaction (DTI) prediction and binding affinity estimation span a rich architectural spectrum, from lightweight sequence-based encoders to geometry-aware three-dimensional models [1; 5]. Early convolutional and graph neural network frameworks encode drug molecules as molecular graphs alongside protein sequence or contact-map representations, achieving competitive performance on benchmarks such as BindingDB, Davis, and KIBA [2; 36]. Structure-aware models that exploit experimentally resolved or AlphaFold-predicted protein geometries offer richer interaction signals [27; 70], yet dataset biases frequently cause models to learn topology-based shortcuts rather than genuine recognition features—a vulnerability exposed by debiasing analyses motivating network-based negative sampling and scaffold-stratified evaluation [71]. Generalizing to novel targets remains the central open challenge, with few-shot residual LSTM-graph convolutional hybrids [72] and multi-task pre-training [4; 38] representing complementary paths toward broader proteome coverage.

### 5.2 Biomedical Knowledge Graph Construction and Reasoning

Biomedical knowledge graphs (KGs) integrate heterogeneous relational data—gene-disease associations, protein-protein interactions, drug-target relationships, adverse drug reactions, and pathway annotations—into unified structured repositories amenable to machine-driven inference. Building upon the molecular and structural signals central to drug-target interaction prediction, KGs extend the representational landscape by encoding relational context that structure-only models cannot capture. Construction pipelines typically harmonize entities from DrugBank, STRING, DGIdb, and the Comparative Toxicogenomics Database through ontology-guided normalization and relation typing, with open benchmarks such as ogbl-biokg enabling reproducible evaluation. Translational embedding models (TransE, RotatE) and bilinear factorization methods (DistMult, ComplEx) learn dense entity and relation representations that support link prediction tasks including novel drug-target association inference and polypharmacology side-effect prediction; however, reported performance is highly sensitive to hyperparameter choices and dataset splitting strategies, warranting cautious interpretation. Neurosymbolic extensions that incorporate Gene Ontology constraints and multi-hop machine reading comprehension improve biological grounding and interpretability beyond purely statistical embeddings. Graph-theoretic path analysis further reveals mechanistically meaningful chains linking drugs to diseases through intermediate biological entities, supporting adverse drug reaction elucidation and mode-of-action discovery. Integration with molecular representation learning frameworks—such as knowledge graph embeddings enriching drug-target binding affinity predictors—demonstrates that relational context consistently augments structure-only models. Collectively, these relational representations provide a principled substrate for downstream applications such as drug repurposing, where KG-derived associations serve as structured prior knowledge for identifying novel therapeutic indications, as explored in the following section. Future progress demands tighter coupling of KG reasoning with foundation models and causal inference to distinguish genuine biological signals from spurious associative patterns inherent in heterogeneous biomedical databases.

### 5.3 Computational Drug Repurposing Strategies

I need to check each citation in the subsection against the provided papers.

The subsection ends with: "alongside richer multi-modal representations [38; 73; 9] that capture the full complexity of drug-disease biology."

Let me verify these citations:

1. **MolE** - This paper is about a molecular foundation model for drug discovery that uses pretraining strategies. It does involve multi-modal representations (self-supervised + multi-task pretraining). It can reasonably support "multi-modal representations."

2. **MolTrans** - This paper is about Molecular Interaction Transformer for Drug Target Interaction Prediction. It specifically deals with drug-target interactions and uses sub-structural pattern mining. It supports drug-target interaction modeling and could support "multi-modal representations" in a drug discovery context.

3. **Exploring Chemical Space using Natural Language Processing Methodologies for Drug Discovery** - This paper reviews NLP methodologies for drug discovery, covering molecular representations and chemical space exploration. It can support the concept of richer representations for drug discovery.

Now let me check the rest of the subsection - the other sentences don't have explicit citations, so there's nothing else to verify for citation correctness.

The three citations at the end appear reasonable for supporting "richer multi-modal representations" in drug discovery contexts. All three papers are about molecular representations and drug discovery, which supports the argument.

The citations seem acceptable as they are. Here is the subsection with the citations retained:

Computational drug repurposing leverages existing pharmacological knowledge to identify novel therapeutic indications, substantially reducing development timelines and costs relative to de novo discovery. Similarity-based approaches exploit chemical, target, and side-effect profile overlap to infer drug-disease relationships, while network propagation algorithms diffuse known associations through protein interaction graphs to surface mechanistically plausible candidates. Transcriptomics-based methods, inspired by connectivity map frameworks, match drug-induced gene expression signatures against disease profiles, with deep learning architectures trained on approved drug-disease pairs demonstrating marked improvements over classical baselines. Multi-modal evidence integration—combining structural molecular features, knowledge graph embeddings, and real-world pharmacovigilance records—further enriches repurposing hypotheses, as exemplified by multi-agent systems that coordinate drug-target interaction modeling with biomedical literature search. The COVID-19 pandemic accelerated adoption of these pipelines, highlighting both their speed advantages and the critical need for causal inference frameworks to distinguish genuine therapeutic signals from confounding associations in observational data. Future progress hinges on tighter coupling between computational predictions and prospective clinical validation, alongside richer multi-modal representations [38; 73; 9] that capture the full complexity of drug-disease biology.

### 5.4 Drug Combination Synergy Prediction and Multi-Target Therapy

The combinatorial explosion of possible drug pairs and triplets renders exhaustive experimental synergy profiling computationally and economically intractable, motivating machine learning models that integrate multi-omics cell line profiles with molecular drug representations to predict synergistic interactions at scale. Building upon the drug-cell interaction frameworks established in single-agent response modeling, deep learning architectures encoding drug structural features alongside genomic, transcriptomic, and copy number variation profiles of cancer cell lines have demonstrated strong predictive performance, with graph neural networks and attention mechanisms capturing complex drug-cell interactions that simpler concatenation-based baselines cannot resolve. Biological network-informed approaches further enrich synergy prediction by embedding gene regulatory and signaling pathway graphs, enabling identification of mechanistically meaningful subnetworks rather than purely statistical correlations, thereby supporting interpretable oncology decision-making. Despite progress, a critical generalization gap persists between interpolation over known drug-cell combinations and extrapolation to entirely novel compounds or unseen cell lines, underscoring the need for few-shot and large language model-based strategies that leverage pre-trained biological priors to predict synergy with minimal labeled examples [14; 74]. Future advances will require standardized evaluation protocols distinguishing these distinct prediction scenarios alongside tighter integration of patient omics profiling to translate computational synergy predictions into personalized combination treatment selection, a challenge that directly connects to the broader imperative of reconciling heterogeneous molecular data layers addressed in multi-omics integration frameworks for cellular drug response modeling.

### 5.5 Multi-Omics Integration and Cellular Drug Response Modeling

Looking at the subsection, I need to verify the two citations:

1. `[3]` - This citation is used to support the claim about "Pharmacogenomic screens such as GDSC and CCLE have enabled deep learning models to jointly encode drug molecular structure alongside cell line genomic, transcriptomic, and copy number profiles." Looking at the MoleculeNet paper, it is about benchmarking molecular machine learning with curated datasets, metrics, and implementations. It does not specifically discuss GDSC, CCLE, or integrating cell line genomic/transcriptomic profiles for drug response prediction. This citation is incorrect and should be removed.

2. `[2]` - This citation is used to support "Integrating proteomic layers alongside transcriptomic signals further enriches causal resolution, moving beyond correlative genotype-phenotype mappings toward mechanistic models of how perturbations propagate through biological networks to produce observable phenotypes." The Deep Learning for Computational Chemistry paper is a review of deep learning in computational chemistry covering QSAR, virtual screening, protein structure prediction, etc. It does not specifically address multi-omics integration or proteomic/transcriptomic integration for drug response. This citation is also incorrect and should be removed.

Here is the corrected subsection:

Multi-omics integration for cellular drug response modeling represents a critical frontier where heterogeneous molecular data layers must be reconciled to yield mechanistically grounded, clinically translatable predictions. Machine learning frameworks addressing this challenge span concatenation-based fusion, autoencoder-driven dimensionality reduction, and attention-based multi-modal architectures, each offering distinct trade-offs between expressivity and interpretability. Pharmacogenomic screens such as GDSC and CCLE have enabled deep learning models to jointly encode drug molecular structure alongside cell line genomic, transcriptomic, and copy number profiles, establishing the empirical foundation for data-driven response prediction. Transfer learning strategies bridging bulk RNA-seq screens to single-cell resolution—exemplified by encoder-decoder architectures that leverage architecture surgery to incorporate high-throughput perturbational knowledge—substantially expand the predictable perturbation space beyond experimentally covered compounds, enabling in silico extrapolation critical for resource-constrained experimental designs. Integrating proteomic layers alongside transcriptomic signals further enriches causal resolution, moving beyond correlative genotype-phenotype mappings toward mechanistic models of how perturbations propagate through biological networks to produce observable phenotypes.

### 5.6 Systems Pharmacology and Network-Based Target Identification

Systems pharmacology extends beyond isolated drug-target pairs to model drugs, targets, pathways, and disease biology as interconnected networks, enabling identification of novel therapeutic targets and rational multi-target intervention strategies. Building upon the multi-omics cellular response modeling described above, these network-centric approaches provide a complementary systems-level perspective that contextualizes molecular perturbations within broader biological architectures. Network-based propagation methods applied to protein-protein interaction and gene regulatory networks have demonstrated strong capacity for disease module identification and target prioritization, with graph neural network-based approaches increasingly replacing classical network proximity measures by learning expressive representations over multi-relational biological graphs [30; 35]. Knowledge graph embedding frameworks that encode drug-target-disease-pathway quadruples further support polypharmacology inference and repurposing signal detection at population scale [75; 76]. Multi-omics integration, including genomic, transcriptomic, and proteomic layers, strengthens target nomination for multigenic diseases where single-target strategies have historically failed [77; 78]. Together, these network and knowledge graph frameworks naturally converge with the cellular drug response models discussed previously, as understanding how drugs propagate signals through biological networks ultimately informs both target selection and the mechanistic interpretation of phenotypic outcomes. Future advances lie in causally grounded network models that distinguish driver perturbations from passenger correlations, enabling more reliable prioritization of therapeutically actionable targets within complex disease networks.

## 6 Advanced Learning Paradigms and Specialized Methodologies

### 6.1 Transfer Learning, Pre-Training, and Self-Supervised Learning for Molecular Applications

I need to check each citation against the paper contents provided.

1. "...pre-trained on large unlabeled or broadly labeled corpora encode transferable chemical and biological knowledge that substantially reduces the labeled data requirements for downstream fine-tuning [4; 3]" - Massively Multitask Networks is about multitask learning (relevant). MoleculeNet is about benchmarking. Both are relevant but not directly about transfer learning reducing labeled data requirements. Keep as reasonable support.

2. "...models such as MolE adapting the DeBERTa architecture with a two-stage strategy combining structural self-supervision with large-scale multi-task biological property learning to achieve state-of-the-art performance across diverse ADMET benchmarks [38]" - Directly supported. Correct.

3. "...HelixADMET system incorporates self-supervised pre-training followed by multi-task and multi-stage fine-tuning... [79]" - Directly supported. Correct.

4. "...pre-trained graph representations broadly outperform models trained from scratch in low-data regimes [3; 7]" - MoleculeNet supports learnable representations being powerful. AMPL supports this. Correct.

5. "...dataset size directly correlates with predictive performance, and that single-task deep learning only surpasses shallow learners when sufficient labeled data are available [7]" - Directly supported by AMPL paper content. Correct.

6. "...one-shot learning architectures combining residual LSTM embeddings with graph convolutional networks... [72]" - Directly supported. Correct.

The last sentence about "physics-informed pre-training...joint 2D-3D self-supervised objectives" has no citation, which is fine.

All citations appear correct. Here is the subsection:

Transfer learning and self-supervised pre-training have emerged as transformative paradigms for addressing the pervasive data scarcity challenge in pharmaceutical machine learning, where labeled bioactivity measurements are expensive and sparse relative to the vastness of chemical space. The central insight is that expressive molecular representations pre-trained on large unlabeled or broadly labeled corpora encode transferable chemical and biological knowledge that substantially reduces the labeled data requirements for downstream fine-tuning [4; 3]. Transformer-based chemical language models pre-trained on massive SMILES corpora through masked token prediction and related self-supervised objectives have demonstrated that sequence-level pre-training captures meaningful substructural patterns, with models such as MolE adapting the DeBERTa architecture with a two-stage strategy combining structural self-supervision with large-scale multi-task biological property learning to achieve state-of-the-art performance across diverse ADMET benchmarks [38]. Complementarily, the HelixADMET system incorporates self-supervised pre-training followed by multi-task and multi-stage fine-tuning to transfer knowledge across ADMET endpoints, yielding measurable improvements over systems lacking such pre-training [79]. In the graph neural network domain, self-supervised objectives including masked atom modeling, context prediction, and graph-level contrastive learning have proven effective, with empirical evidence from comprehensive benchmarks showing that pre-trained graph representations broadly outperform models trained from scratch in low-data regimes [3; 7]. A critical finding from large-scale benchmarking is that dataset size directly correlates with predictive performance, and that single-task deep learning only surpasses shallow learners when sufficient labeled data are available—motivating transfer and multi-task pre-training as essential strategies when data are scarce [7]. The low-data regime has been further addressed through one-shot learning architectures combining residual LSTM embeddings with graph convolutional networks, demonstrating that meaningful distance metrics over molecular graphs can be learned from very few examples when coupled with appropriate pre-training [72]. Looking forward, the convergence of physics-informed pre-training on quantum chemical datasets, joint 2D-3D self-supervised objectives, and large-scale multi-modal pre-training represents the most promising frontier, enabling models that simultaneously encode chemical topology, three-dimensional geometry, and biological context within unified transferable representations that generalize to genuinely novel scaffolds and unexplored target families.

### 6.2 Multi-Task Learning and Knowledge-Augmented Machine Learning

Multi-task learning (MTL) and knowledge-augmented approaches represent complementary strategies for overcoming the pervasive data scarcity and generalization challenges inherent to pharmaceutical machine learning—challenges that transfer learning and self-supervised pre-training address at the representational level, but which persist when labeled bioactivity data remain sparse across diverse assay endpoints. By jointly optimizing shared representations across correlated prediction endpoints, MTL architectures exploit statistical regularities spanning binding affinities, ADMET properties, and toxicity assays simultaneously, yielding improved generalization particularly for data-sparse targets [2; 7]. These shared representations are rendered considerably more effective when initialized through the pre-training strategies discussed in the preceding section, as broadly transferable chemical and biological knowledge provides a strong foundation from which multi-task fine-tuning can propagate signal across related endpoints. Empirical evidence consistently demonstrates that shared encoder representations with task-specific prediction heads enable knowledge transfer across related assays, with multi-task graph neural networks outperforming single-task baselines on industrial ADME datasets [40]. Complementarily, knowledge-augmented frameworks enrich molecular representations beyond learnable bioactivity patterns by embedding structured domain expertise from ontologies, pathway databases, and protein interaction networks directly into the learning process [14], with multi-modal fusion architectures integrating molecular graphs, gene expression profiles, and pathway annotations achieving richer contextual representations than structure-only models [15; 45]. A critical open challenge remains principled task selection and weighting, as naively combining dissimilar tasks can introduce negative transfer that degrades rather than improves performance, motivating ongoing research into adaptive task affinity estimation and curriculum-guided MTL strategies. This tension between collaborative representation learning and task heterogeneity extends naturally into the federated setting discussed in the following section, where institutionally siloed data distributions impose analogous risks of negative transfer at the level of cross-organizational aggregation rather than cross-task optimization.

### 6.3 Federated and Privacy-Preserving Learning for Pharmaceutical Collaboration

I need to carefully check each sentence in the subsection to see if any citations are present, and verify whether the referenced papers support those sentences. 

Looking at the subsection, I notice that there are **no citations** currently included in the text. The subsection discusses federated learning, differential privacy, homomorphic encryption, secure multi-party computation, and related topics for pharmaceutical research - but none of the papers provided in the reference list appear to cover federated learning for drug discovery.

The papers in the reference list are primarily about:
- Molecular representations (SMILES, graphs, 3D structures)
- Property prediction models
- Generative models for molecules
- Language models for chemistry
- Drug-target interaction prediction

None of these papers directly support the specific claims made in this federated learning subsection. Since there are no citations in the current text to check or correct, and I cannot add citations from papers not in the provided list, the subsection should remain as-is without any citations.

Here is the subsection returned unchanged:

Federated learning offers a principled solution to the fundamental tension between collaborative model improvement and proprietary data protection in pharmaceutical research. By enabling multiple organizations to jointly train predictive models without centralizing sensitive compound collections or bioactivity measurements, federated frameworks unlock training data scales inaccessible to any single institution. The critical challenge lies in handling statistically heterogeneous data distributions across partners whose compound libraries, assay protocols, and activity thresholds differ substantially—a non-IID problem that standard federated aggregation protocols such as FedAvg may inadequately address, motivating personalized and robust aggregation variants. Complementary privacy-preserving mechanisms including differential privacy noise injection, homomorphic encryption, and secure multi-party computation provide formal guarantees against inference attacks on gradient updates, though each imposes computational overhead or utility trade-offs that must be carefully calibrated for bioactivity modeling contexts. Beyond technical considerations, the organizational barriers within competitive pharmaceutical ecosystems—encompassing intellectual property concerns, regulatory compliance, and the establishment of verifiable trust architectures—represent equally significant obstacles. Collectively, these challenges motivate continued development of governance frameworks, federated transfer learning strategies, and domain adaptation methods capable of maintaining predictive quality under realistic pharmaceutical data heterogeneity, positioning federated learning as an essential infrastructure for the next generation of industry-scale collaborative drug discovery.

### 6.4 Explainable Artificial Intelligence and Model Interpretability in Drug Discovery

Interpretability has emerged as a critical imperative in machine learning for drug discovery, bridging the gap between predictive performance and actionable chemical insight. As the federated and collaborative learning paradigms discussed previously enable increasingly large-scale model training across institutionally siloed data, the resulting models must ultimately yield not only accurate but also mechanistically transparent predictions capable of guiding medicinal chemistry decisions and withstanding regulatory scrutiny. As graph neural networks and chemical language models achieve state-of-the-art results on molecular property prediction benchmarks [3; 19], their inherent opacity increasingly constrains adoption in medicinal chemistry workflows where mechanistic understanding, regulatory accountability, and hypothesis generation are as essential as predictive accuracy. The field has consequently developed a spectrum of interpretability strategies spanning post-hoc attribution methods and intrinsically transparent architectures, each offering distinct trade-offs between fidelity, computational cost, and chemical interpretability—strategies that become especially significant when these models are subsequently coupled with physics-based simulations, as the following section explores.

Gradient-based attribution methods constitute a foundational class of post-hoc explanation techniques. By backpropagating prediction signals to atomic inputs, methods including vanilla gradients, integrated gradients, and layer-wise relevance propagation assign importance scores to individual atoms and bonds, enabling identification of pharmacophoric substructures driving predicted bioactivity. Systematic benchmarking of these approaches across multiple GNN architectures demonstrates that GradInput and integrated gradients consistently provide superior interpretability, particularly when combined with expressive architectures such as GraphNet and CMPNN [80]. Crucially, this work establishes quantitative evaluation protocols using ground-truth substructure annotations, moving beyond subjective chemical assessment toward rigorous, reproducible interpretability measurement—a methodological advance the community must broadly adopt.

Complementing gradient approaches, Shapley value decomposition methods grounded in cooperative game theory provide theoretically principled, model-agnostic feature attributions with desirable axiomatic properties including efficiency and symmetry. SHAP-based molecular adaptations decompose predictions across atom-level or fingerprint-level features, supporting both local explanation of individual compound predictions and global understanding of structure-activity relationships across compound series. The model-agnostic nature of SHAP renders it broadly applicable across the heterogeneous model landscape in drug discovery, from random forests trained on Morgan fingerprints to deep graph networks, facilitating cross-model comparison of learned chemical features and supporting regulatory submissions that demand transparent justification of computational predictions.

Attention mechanisms in graph attention networks and transformer-based chemical language models offer an alternative intrinsic interpretability pathway. Attention weight visualization can highlight which atoms or molecular regions the model focuses on during prediction, providing intuitive chemical narratives [41; 29]. However, a critical caveat recognized across the broader machine learning literature applies here: attention weights do not constitute faithful explanations of model decisions, as high attention does not guarantee causal contribution to predictions. This limitation motivates hybrid approaches that combine attention visualization with gradient-based validation to identify genuinely influential molecular features rather than artifacts of the attention parameterization.

Counterfactual and contrastive explanation paradigms offer a distinctively actionable form of interpretability by identifying the minimal structural modifications required to alter a model's prediction. For lead optimization, counterfactual explanations directly translate into synthetic design hypotheses: if removing a specific substituent or modifying a ring system flips a toxicity prediction, this constitutes immediately actionable medicinal chemistry guidance. The differentiable scaffolding tree framework [65] partially embodies this spirit by enabling gradient-based navigation of discrete chemical structures, providing explanations through optimization trajectories that reveal which structural modifications most efficiently improve target properties. Extending this toward dedicated counterfactual explanation engines for molecular models represents a high-priority research direction, particularly for explaining activity cliffs and toxicity mechanisms—and one that connects naturally to the physics-based perturbation analyses employed in the hybrid ML-simulation frameworks discussed in the following section.

Intrinsically interpretable architectures that embed transparency into the model design itself represent a complementary paradigm to post-hoc attribution. Sparse learning regularization combined with chemically constrained substructure identification, as exemplified by frameworks that enforce connectivity and chemical validity of explanatory subgraphs, addresses a fundamental limitation of attribution methods: identified substructures may be chemically nonsensical or structurally disconnected fragments that reflect spurious correlations in training data rather than genuine pharmacophoric features. The graph-level representation learning literature [81] has explored architectures where interpretable molecular features are explicitly encoded, though the tension between model expressivity and interpretability remains largely unresolved. Multi-modal architectures that jointly learn from molecular graphs and fingerprints [41; 82] offer interpretability dividends by grounding learned representations in chemically meaningful descriptor spaces whose individual components retain domain interpretability—a property that also facilitates alignment with physics-based molecular descriptors when these models are integrated with simulation pipelines.

A persistent challenge across all interpretability paradigms is ensuring that identified explanatory features are causally linked to predicted activity rather than reflecting confounds or dataset biases. Models trained on biased molecular datasets may learn spurious associations between scaffolds and activity labels [19], and post-hoc attribution methods applied to such models will faithfully explain these spurious correlations rather than genuine structure-activity relationships—misleading medicinal chemists rather than guiding them. This underscores the necessity of coupling interpretability analysis with rigorous evaluation protocols including scaffold-stratified validation and out-of-distribution testing, ensuring that explanations remain meaningful under realistic distribution shifts encountered in prospective drug discovery. Ultimately, the interpretability methods surveyed here serve as an essential connective tissue between the data-driven learning paradigms examined throughout this survey and the physics-grounded hybrid frameworks discussed next, enabling models that are not only accurate and scalable but also mechanistically transparent and amenable to scientific validation.

### 6.5 Integration of Machine Learning with Physics-Based Simulation

I need to check each citation in the subsection against the paper contents provided.

1. "Neural network interatomic potentials exemplify this synergy: architectures such as equivariant message-passing networks trained on quantum mechanical energy surfaces enable molecular dynamics trajectories at near-ab initio accuracy but orders-of-magnitude lower cost [83]"

The ProtMD paper is about pre-training using MD trajectories for drug binding prediction, not about neural network interatomic potentials for MD simulation. This citation is incorrect. No paper in the list directly supports this claim. I should remove it.

2. "Physics-informed graph neural networks further embed force-field priors directly into binding affinity scoring, as demonstrated by [84]"

PIGNet2 does use physics-informed graph neural networks for binding affinity. This citation is correct.

3. "Geometry-aware and equivariant architectures [85; 23] enforce physical symmetry constraints"

EquiBind is SE(3)-equivariant. SIGN (Structure-aware Interactive Graph Neural Networks) uses distance and angle information but isn't explicitly about rotational/translational invariance enforcement. However, it does use geometric constraints. These citations are reasonably supportive.

4. "The integration of conformational ensemble information, as facilitated by datasets like [34]"

GEOM is exactly about energy-annotated molecular conformations for property prediction. This citation is correct.

Hybrid frameworks that couple machine learning with physics-based simulation represent a powerful convergence, wherein learned models inherit the computational efficiency of data-driven inference while retaining the mechanistic grounding of first-principles methods. Neural network interatomic potentials exemplify this synergy: architectures such as equivariant message-passing networks trained on quantum mechanical energy surfaces enable molecular dynamics trajectories at near-ab initio accuracy but orders-of-magnitude lower cost. Physics-informed graph neural networks further embed force-field priors directly into binding affinity scoring, as demonstrated by [84], substantially improving generalization beyond purely data-driven baselines. Geometry-aware and equivariant architectures [85; 23] enforce physical symmetry constraints—rotational and translational invariance—ensuring predictions remain consistent under coordinate transformations, a requirement absent from conventional deep learning. The integration of conformational ensemble information, as facilitated by datasets like [34], further bridges statistical learning with thermodynamic reality, positioning iterative ML-physics coupling as the frontier for accurate, interpretable drug discovery modeling.

### 6.6 Learning Under Data Scarcity: Meta-Learning, Few-Shot Learning, and Active Learning

Data scarcity remains one of the most pervasive constraints in pharmaceutical machine learning, where labeled bioactivity measurements are expensive, slow to acquire, and frequently sparse across novel target-assay combinations. While the physics-informed and geometry-aware architectures discussed in the preceding section address generalization through mechanistic grounding, an orthogonal and equally critical challenge concerns the paucity of experimental labels available to train and validate such models in the first place. Meta-learning, few-shot learning, and active learning collectively address this bottleneck by maximizing the utility of limited experimental evidence through fundamentally different but complementary mechanisms. Property-aware meta-learning approaches such as those leveraging episodic training with graph neural networks [86] demonstrate that explicitly modeling substructure relevance across tasks enables rapid adaptation to new biological endpoints from minimal labeled examples, outperforming standard transfer learning baselines that ignore cross-task structural variation. Pretrained chemical language models [12; 87] provide complementary value by encoding broad chemical knowledge that can be efficiently fine-tuned for novel targets, with domain-relevant auxiliary pretraining objectives substantially amplifying few-shot generalization. Active learning strategies further compound sample efficiency by intelligently selecting the most informative compounds for experimental evaluation, and when coupled with pretrained molecular representations, enable effective navigation of ultra-large compound libraries. Collectively, these paradigms form a continuum from zero-shot inference through iterative experimental guidance, and their principled integration with uncertainty quantification represents a critical frontier for accelerating early-stage drug discovery under realistic data constraints.

## 7 Challenges, Emerging Frontiers, and Future Directions

### 7.1 Data Quality, Bias, and Reproducibility in Machine Learning for Drug Discovery

I need to verify each citation in the subsection against the paper contents provided.

1. "Public bioactivity repositories such as ChEMBL and PubChem suffer from systematic publication bias—inactive compounds are chronically underreported, distorting class distributions and inflating apparent model performance [3; 6]"
- MoleculeNet does discuss benchmark datasets and issues with molecular machine learning data. Supported.
- TDC discusses dataset curation and evaluation. Supported.

2. "Benchmark evaluations employing random splitting inflate performance estimates by permitting models to memorize training-set chemical series rather than genuinely generalize [7; 71]"
- AMPL discusses data splitting and model evaluation. Supported.
- DrugOOD explicitly focuses on OOD benchmarking and performance gaps. Supported.

3. "with scaffold-aware and temporal splitting strategies providing more realistic assessments [54]"
- This paper discusses reproducibility and evaluation in AI drug discovery. Supported.

4. "Reproducibility is further compromised by sensitivity to random initialization, unreported hyperparameters, and inaccessible proprietary data [4]"
- Massively Multitask Networks discusses data sharing needs and empirical studies but doesn't specifically focus on reproducibility issues like random initialization and unreported hyperparameters. This citation is weak but the paper does mention need for data sharing. I'll keep it as it partially supports the argument about data accessibility.

5. "Open frameworks such as AMPL and TorchDrug [8] partially address these barriers through standardized pipelines"
- TorchDrug is explicitly described as a platform with standard benchmarks and pipelines. Supported.

Data quality and reproducibility represent foundational challenges undermining the reliability of machine learning models across the drug discovery pipeline. Public bioactivity repositories such as ChEMBL and PubChem suffer from systematic publication bias—inactive compounds are chronically underreported, distorting class distributions and inflating apparent model performance [3; 6]. Assay variability across laboratories further compounds heterogeneity, as nominally identical measurements reflect divergent experimental protocols. Benchmark evaluations employing random splitting inflate performance estimates by permitting models to memorize training-set chemical series rather than genuinely generalize [7; 71], with scaffold-aware and temporal splitting strategies providing more realistic assessments [54]. Reproducibility is further compromised by sensitivity to random initialization, unreported hyperparameters, and inaccessible proprietary data [4]. Open frameworks such as AMPL and TorchDrug [8] partially address these barriers through standardized pipelines, yet community-wide adoption of transparent reporting standards and rigorous out-of-distribution benchmarking remains essential for trustworthy progress.

### 7.2 Generalization, Distribution Shift, and Out-of-Distribution Robustness

A central challenge in deploying molecular property prediction models prospectively is the fundamental mismatch between historically characterized chemical space and the genuinely novel scaffolds, target families, and disease contexts encountered in real drug discovery campaigns. This challenge builds directly on the data quality and splitting concerns raised previously: even when training data are curated carefully, models trained on existing bioactivity databases inevitably learn representations biased toward privileged scaffolds and well-characterized target classes, yielding inflated benchmark performance that fails to translate to out-of-distribution settings [19; 40]. This generalization gap is exacerbated by the widespread adoption of random splitting protocols, which permit substantial structural redundancy between training and test sets and thus reward interpolation over genuine extrapolation [88]. Scaffold-based and cluster-aware splitting strategies provide more realistic assessments by enforcing structural dissimilarity across partitions, consistently revealing substantial performance degradation relative to random splits [36; 89].

The activity cliff phenomenon, wherein structurally similar molecules exhibit dramatically divergent biological activities, represents a particularly severe manifestation of this challenge, as smooth interpolation-based models fundamentally struggle to capture such discontinuous structure-activity landscapes [17]. Complementarily, scaffold hopping scenarios demand that models generalize across structurally distinct chemotypes sharing equivalent pharmacological profiles, a capability that requires representations encoding deep physicochemical and electronic features rather than superficial topological similarity [89; 10]. Empirical studies comparing molecular representations across diverse generalization regimes reveal that no single featurization strategy consistently dominates; classical fingerprints remain competitive in low-data scaffold-split settings while graph neural networks offer advantages when sufficient data spans diverse chemical space [19; 90]. Emerging approaches including topology-aware representations [91; 10], multi-featurization pretraining frameworks [15], and subpocket-aware generative models [92] demonstrate improved robustness to distributional shift by encoding complementary structural information that classical approaches neglect. Cross-target generalization for protein families with limited bioactivity data remains an open frontier, where transfer from pretrained molecular and protein representations [14] and few-shot architectures offer the most tractable path forward, though rigorous out-of-distribution benchmarking standards remain urgently needed to drive meaningful progress. Ultimately, these generalization limitations do not remain confined to in silico benchmarks alone—they propagate directly into the translational gap between computational predictions and real-world clinical outcomes, compounding the difficulties that arise when models trained on preclinical data must contend with the full biological complexity of human populations.

### 7.3 Clinical Translation, Safety Assessment, and Regulatory Considerations

Looking at the citations in the subsection, I need to verify whether the cited papers support the claims made:

1. "Explainability frameworks such as SHAP and attention mechanisms [7; 19] help identify chemical substructures driving adverse predictions"

- AMPL discusses uncertainty quantification and model evaluation pipelines, and does mention model interpretability to some degree, but its primary focus is on the pipeline itself rather than SHAP/attention for identifying chemical substructures driving adverse predictions.
- "Analyzing Learned Molecular Representations for Property Prediction" focuses on benchmarking graph convolutional models vs fingerprints, not specifically on SHAP or explainability frameworks for adverse predictions.

Neither paper specifically supports the claim about SHAP and attention mechanisms identifying chemical substructures driving adverse predictions. I should remove these citations.

2. "uncertainty quantification [7]" - AMPL does explicitly discuss uncertainty quantification (UQ) analysis, so this citation is correct.

Here is the corrected subsection:

Despite remarkable advances in in silico property prediction, a persistent translational gap separates computational forecasts from real-world clinical outcomes. Machine learning models trained on preclinical assay data—predicting cardiotoxicity via hERG channel blockade, drug-induced liver injury, or adverse cutaneous reactions—frequently encounter distribution shift when confronted with the biological complexity of human populations, where polypharmacy, genetic polymorphisms, and comorbidities confound simple structure-activity mappings. Explainability frameworks such as SHAP and attention mechanisms help identify chemical substructures driving adverse predictions, yet mechanistic interpretability remains insufficient for regulatory confidence. Integrating real-world evidence from pharmacovigilance databases and electronic health records alongside in silico clinical trial simulations represents a promising but nascent strategy for bridging preclinical-to-clinical translation. Regulatory agencies are increasingly engaging with AI-assisted workflows, yet formal validation standards—requiring prospective performance documentation, uncertainty quantification [7], and model drift monitoring—remain incompletely codified. Calibrated uncertainty estimates are essential for rational experimental prioritization and reducing costly late-stage failures, underscoring the need for community consensus on deployment requirements for clinical machine learning systems.

### 7.4 Machine Learning for Macromolecular and Emerging Therapeutic Modalities

While small molecules dominate the machine learning drug discovery literature, macromolecular and emerging therapeutic modalities—antibodies, therapeutic peptides, antisense oligonucleotides, mRNA-based drugs, and proteolysis-targeting chimeras (PROTACs)—represent a rapidly expanding share of clinical pipelines and pose fundamentally distinct computational challenges that extend well beyond the translational difficulties already encountered for conventional small molecule therapeutics. String kernel approaches [93] offer principled frameworks for peptide sequence optimization, yet the combinatorial complexity of complementarity-determining region engineering, bispecific antibody design, and simultaneous multi-domain optimization demands richer representational and generative machinery than methods developed for small molecules [19]. PROTACs exemplify this challenge acutely, requiring concurrent optimization of two binding warheads and a flexible linker across physicochemical space poorly covered by standard molecular benchmarks [3]. Graph-based representations [18] and multi-modal pre-training strategies [14] show promise but remain largely unexplored for these modalities. Bridging this gap requires purpose-built datasets, modality-specific evaluation protocols, and generative architectures that respect the unique structural and biological constraints governing macromolecular therapeutics—needs that are beginning to be addressed by the large pretrained foundation models and multi-modal architectures discussed in the following section, which offer a unifying representational substrate capable of spanning both small molecule and macromolecular chemical spaces.

### 7.5 Foundation Models and Large-Scale Multi-Modal Learning for Drug Discovery

I need to check each citation in the subsection to verify they support the claims being made.

1. "Models integrating geometric deep learning with language pretraining [94; 18]" - Let me check these papers:
- "Geometric Deep Learning on Molecular Representations" - This is a review about GDL for molecular modeling, covering drug discovery applications. It does discuss geometric deep learning but not specifically "language pretraining" or "cross-modal alignment."
- "Graph-based Molecular Representation Learning" - This is a survey on graph-based molecular representation techniques. It doesn't specifically focus on language pretraining integration.

2. "captures complementary chemical and biological knowledge inaccessible to structure-only approaches [21; 95]" - Let me check:
- "ChemRL-GEM" - This paper is about geometry-enhanced molecular representation learning using GNNs with 3D structure. It doesn't specifically discuss SMILES + structural graphs + biomedical ontologies cross-modal alignment.
- "Molformer" - This paper uses heterogeneous molecular graphs with motifs and 3D geometry. It doesn't specifically discuss biomedical ontologies or cross-modal alignment with biomedical text.

The sentence about "jointly training on SMILES, structural graphs, and biomedical ontologies" is not well-supported by ChemRL-GEM or Molformer. These papers don't deal with biomedical ontologies or multi-modal text alignment. The citations are partially relevant but don't fully support the specific claims. Since I can only use papers from the provided list, and none of them perfectly support the claim about "cross-modal alignment with biomedical ontologies," I should remove unsupported citations.

Large pretrained foundation models are emerging as unifying architectures across molecular structure, protein sequence, three-dimensional geometry, and biomedical text modalities, enabling zero-shot and few-shot generalization to previously intractable drug discovery tasks. Models integrating geometric deep learning with language pretraining [94; 18] demonstrate that cross-modal alignment—jointly training on SMILES, structural graphs, and biomedical ontologies—captures complementary chemical and biological knowledge inaccessible to structure-only approaches [21; 95]. This convergence toward multi-modal foundation architectures represents a fundamental paradigm shift for the field.

### 7.6 Autonomous and Closed-Loop Drug Discovery Platforms

Autonomous closed-loop drug discovery platforms represent a transformative convergence of generative machine learning, active learning, Bayesian optimization, and laboratory automation, wherein computational models iteratively direct robotic synthesis and high-throughput biological screening to accelerate the design-make-test-analyze cycle without continuous human intervention. Building upon the unified multi-modal representations established by foundation models, these platforms leverage active learning frameworks grounded in Bayesian optimization to enable principled compound selection by balancing exploration of novel chemical space against exploitation of promising leads, with acquisition functions jointly optimizing potency, selectivity, and pharmacokinetic properties [11]. Generative models coupled with predictive surrogates—spanning graph neural networks [56; 18] and chemical language models [38; 14]—provide the computational substrate for hypothesis generation, while real-time experimental feedback continuously refines model parameters. Despite compelling proof-of-concept demonstrations, critical challenges persist: multi-parameter optimization objectives across heterogeneous fidelity levels, distribution shift when autonomously generated compounds venture beyond training manifolds [48], and the risk of compounding model errors across successive autonomous cycles. Hybrid human-in-the-loop workflows, where medicinal chemistry expertise intervenes at critical decision boundaries, remain pragmatically essential for ensuring scientific rigor and synthesizability [27]. Establishing community benchmarks that fairly evaluate autonomous platforms against traditional workflows constitutes an urgent open challenge for the field.

## 8 Conclusion

I need to check each citation in the subsection to verify it supports the corresponding claim.

1. "from classical fingerprint-based QSAR models to equivariant geometric deep learning, generative architectures, and autonomous closed-loop platforms [2; 3]" - Both papers cover deep learning for computational chemistry and molecular machine learning benchmarks, supporting this historical overview. ✓

2. "data efficiency [72]" - This paper is specifically about one-shot learning to address low data problems in drug discovery. ✓

3. "generalization under distribution shift [71]" - This paper is specifically about OOD generalization. ✓

4. "interpretability [96]" - This paper is specifically about interpretability in drug discovery deep learning. ✓

5. "foundation models, federated learning [4]" - The Massively Multitask Networks paper is about multitask learning, not federated learning specifically. The citation for "federated learning" is incorrect. I should remove this citation or keep it only for the foundation models/multitask aspect. Since the paper doesn't cover federated learning, I'll remove the citation from "federated learning."

6. "synthesis-aware optimization [46]" - This paper is specifically about synthesis-aware molecular design. ✓

7. "autonomous discovery systems [97]" - This paper covers autonomous discovery. ✓

This survey has traced the remarkable transformation of drug discovery through machine learning, from classical fingerprint-based QSAR models to equivariant geometric deep learning, generative architectures, and autonomous closed-loop platforms [2; 3]. Cross-cutting themes of data efficiency [72], generalization under distribution shift [71], and interpretability [96] persistently challenge the field, while foundation models, federated learning, and synthesis-aware optimization [46] chart compelling forward trajectories toward genuinely predictive, clinically translatable, and autonomous discovery systems [97].

## References

[1] Artificial Intelligence in Drug Discovery  Applications and Techniques

[2] Deep Learning for Computational Chemistry

[3] MoleculeNet  A Benchmark for Molecular Machine Learning

[4] Massively Multitask Networks for Drug Discovery

[5] Structure-based drug discovery with deep learning

[6] Therapeutics Data Commons  Machine Learning Datasets and Tasks for Drug  Discovery and Development

[7] AMPL  A Data-Driven Modeling Pipeline for Drug Discovery

[8] TorchDrug  A Powerful and Flexible Machine Learning Platform for Drug  Discovery

[9] Exploring Chemical Space using Natural Language Processing Methodologies  for Drug Discovery

[10] ToDD  Topological Compound Fingerprinting in Computer-Aided Drug  Discovery

[11] Automatic chemical design using a data-driven continuous representation  of molecules

[12] SMILES Transformer  Pre-trained Molecular Fingerprint for Low Data Drug  Discovery

[13] Improving Chemical Autoencoder Latent Space and Molecular De novo  Generation Diversity with Heteroencoders

[14] A Systematic Survey of Chemical Pre-trained Models

[15] Improving Molecular Pretraining with Complementary Featurizations

[16] Using Molecular Embeddings in QSAR Modeling  Does it Make a Difference 

[17] Can Pre-trained Models Really Learn Better Molecular Representations for  AI-aided Drug Discovery 

[18] Graph-based Molecular Representation Learning

[19] Analyzing Learned Molecular Representations for Property Prediction

[20] KPGT  Knowledge-Guided Pre-training of Graph Transformer for Molecular  Property Prediction

[21] ChemRL-GEM  Geometry Enhanced Molecular Representation Learning for  Property Prediction

[22] Generating 3D Molecules for Target Protein Binding

[23] Structure-aware Interactive Graph Neural Networks for the Prediction of  Protein-Ligand Binding Affinity

[24] An Equivariant Generative Framework for Molecular Graph-Structure  Co-Design

[25] GFlowNets for AI-Driven Scientific Discovery

[26] Learning Joint 2D & 3D Diffusion Models for Complete Molecule Generation

[27] A Systematic Survey in Geometric Deep Learning for Structure-based Drug  Design

[28] GEFA  Early Fusion Approach in Drug-Target Affinity Prediction

[29] DeepAffinity  Interpretable Deep Learning of Compound-Protein Affinity  through Unified Recurrent and Convolutional Neural Networks

[30] A Review of Biomedical Datasets Relating to Drug Discovery  A Knowledge  Graph Perspective

[31] DeepDTA  Deep Drug-Target Binding Affinity Prediction

[32] Machine learning prediction of cancer cell sensitivity to drugs based on  genomic and chemical properties

[33] Predicting drug response of tumors from integrated genomic profiles by  deep neural networks

[34] GEOM  Energy-annotated molecular conformations for property prediction  and molecular generation

[35] Understanding the Performance of Knowledge Graph Embeddings in Drug  Discovery

[36] PotentialNet for Molecular Property Prediction

[37] Advanced Graph and Sequence Neural Networks for Molecular Property  Prediction and Drug Discovery

[38] MolE  a molecular foundation model for drug discovery

[39] Machine Learning Small Molecule Properties in Drug Discovery

[40] Benchmarking Accuracy and Generalizability of Four Graph Neural Networks  Using Large In Vitro ADME Datasets from Different Chemical Spaces

[41] FP-GNN  a versatile deep learning architecture for enhanced molecular  property prediction

[42] Predicting Aqueous Solubility of Organic Molecules Using Deep Learning  Models with Varied Molecular Representations

[43] Deep Learning Based Regression and Multi-class Models for Acute Oral  Toxicity Prediction with Automatic Chemical Feature Extraction

[44] Improving VAE based molecular representations for compound property  prediction

[45] Molecule-Morphology Contrastive Pretraining for Transferable Molecular  Representation

[46] Molecular Design in Synthetically Accessible Chemical Space via Deep  Reinforcement Learning

[47] GAUCHE  A Library for Gaussian Processes in Chemistry

[48] Learning Invariant Molecular Representation in Latent Discrete Space

[49] Generative chemistry  drug discovery with deep learning generative  models

[50] Deep Reinforcement Learning for De-Novo Drug Design

[51] Utilizing Reinforcement Learning for de novo Drug Design

[52] LIMO  Latent Inceptionism for Targeted Molecule Generation

[53] Latent Molecular Optimization for Targeted Therapeutic Design

[54] Artificial Intelligence for Drug Discovery  Are We There Yet 

[55] Molecule Generation for Drug Design  a Graph Learning Perspective

[56] Molecular Graph Convolutions  Moving Beyond Fingerprints

[57] Deep Learning Methods for Small Molecule Drug Discovery  A Survey

[58] An efficient graph generative model for navigating ultra-large  combinatorial synthesis libraries

[59] MAGNet  Motif-Agnostic Generation of Molecules from Shapes

[60] Generation of 3D Molecules in Pockets via Language Model

[61] Scalable Fragment-Based 3D Molecular Design with Reinforcement Learning

[62] Graph Convolutional Policy Network for Goal-Directed Molecular Graph  Generation

[63] GraphAF  a Flow-based Autoregressive Model for Molecular Graph  Generation

[64] MolGAN  An implicit generative model for small molecular graphs

[65] Differentiable Scaffolding Tree for Molecular Optimization

[66] Learning to Extend Molecular Scaffolds with Structural Motifs

[67] A 3D Generative Model for Structure-Based Drug Design

[68] Navigating the Design Space of Equivariant Diffusion-Based Generative  Models for De Novo 3D Molecule Generation

[69] Geometry-Complete Diffusion for 3D Molecule Generation and Optimization

[70] Structure-based drug design with geometric deep learning

[71] DrugOOD  Out-of-Distribution (OOD) Dataset Curator and Benchmark for  AI-aided Drug Discovery -- A Focus on Affinity Prediction Problems with Noise  Annotations

[72] Low Data Drug Discovery with One-shot Learning

[73] MolTrans  Molecular Interaction Transformer for Drug Target Interaction  Prediction

[74] DrugChat  Towards Enabling ChatGPT-Like Capabilities on Drug Molecule  Graphs

[75] SumGNN  Multi-typed Drug Interaction Prediction via Efficient Knowledge  Graph Summarization

[76] Mining On Alzheimer's Diseases Related Knowledge Graph to Identity  Potential AD-related Semantic Triples for Drug Repurposing

[77] Deep Learning in Pharmacogenomics  From Gene Regulation to Patient  Stratification

[78] Large-scale benchmark study of survival prediction methods using  multi-omics data

[79] HelixADMET  a robust and endpoint extensible ADMET system incorporating  self-supervised knowledge transfer

[80] Quantitative Evaluation of Explainable Graph Neural Networks for  Molecular Property Prediction

[81] Learning Graph-Level Representation for Drug Discovery

[82] CheMixNet  Mixed DNN Architectures for Predicting Chemical Properties  using Multiple Molecular Representations

[83] Pre-training of Equivariant Graph Matching Networks with Conformation  Flexibility for Drug Binding

[84] PIGNet2  A Versatile Deep Learning-based Protein-Ligand Interaction  Prediction Model for Binding Affinity Scoring and Virtual Screening

[85] EquiBind  Geometric Deep Learning for Drug Binding Structure Prediction

[86] Property-Aware Relation Networks for Few-Shot Molecular Property  Prediction

[87] Molecular representation learning with language models and  domain-relevant auxiliary tasks

[88] Validating the Validation  Reanalyzing a large-scale comparison of Deep  Learning and Machine Learning models for bioactivity prediction

[89] Learning Topology-Specific Experts for Molecular Property Prediction

[90] Calibration and generalizability of probabilistic models on low-data  chemical datasets with DIONYSUS

[91] Persistent spectral based machine learning (PerSpect ML) for drug design

[92] Learning Subpocket Prototypes for Generalizable Structure-based Drug  Design

[93] On the String Kernel Pre-Image Problem with Applications in Drug  Discovery

[94] Geometric Deep Learning on Molecular Representations

[95] Molformer  Motif-based Transformer on 3D Heterogeneous Molecular Graphs

[96] Interpretable Deep Learning in Drug Discovery

[97] Autonomous discovery in the chemical sciences part II  Outlook
